GHRH analog is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-10-08. Numbers and descriptions here follow the published literature rather than marketing material.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | Matches human GHRH(1-44) length |
| N-terminal modification | trans-3-hexenoyl group | Confers resistance to dipeptidyl peptidase IV |
| Appearance | White to off-white powder | Typically supplied lyophilized in a sealed vial |
| Solubility class | Freely soluble in water | Hydrophilic peptide; polar solvent compatible |
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Wallace, following on earlier work by de Candolle, Humboldt and Darwin, made major contributions to zoogeography. Because of his interest in the transmutation hypothesis, he paid particular attention to the geographical distribution of closely allied species during his field work first in South America and then in the Malay Archipelago. While in the archipelago he identified the Wallace line, which runs through the Spice Islands dividing the fauna of the archipelago between an Asian zone and a New Guinea/Australian zone. His key question, as to why the fauna of islands with such similar climates should be so different, could only be answered by considering their origin. In 1876 he wrote The Geographical Distribution of Animals, which was the standard reference work for over half a century, and a sequel, Island Life, in 1880 that focused on island biogeography. He extended the six-zone system developed by Philip Sclater for describing the geographical distribution of birds to animals of all kinds. His method of tabulating data on animal groups in geographic zones highlighted the discontinuities; and his appreciation of evolution allowed him to propose rational explanations, which had not been done before.
== Mechanism of action == The perceived sweetness of aspartame (and other sweet substances like acesulfame potassium) in humans is due to its binding of the heterodimer G protein-coupled receptor formed by the proteins TAS1R2 and TAS1R3. Rodents do not experience aspartame as sweet-tasting, due to differences in their taste receptors.
== Prout's Hypothesis == Prout's hypothesis was an early 19th-century attempt to explain the properties of the chemical elements using the internal structure of the atom. In 1815, the English chemist William Prout observed that the atomic weights that had been measured were integer multiples of the atomic weight of hydrogen. Prout's hypothesis remained influential in chemistry throughout the 1820s. However, more careful measurements of the atomic weights, such as those compiled by Jöns Jakob Berzelius in 1828 or Edward Turner in 1832, appeared to disprove it. In particular the atomic weight of chlorine, which is 35.45 times that of hydrogen, could not at the time be explained in terms of Prout's hypothesis. It would take the better part of a century for this problem to be resolved.
Sources: en.wikipedia.org
Actin networks give mechanical support to cells and provide trafficking routes through the cytoplasm to aid signal transduction. Rapid assembly and disassembly of actin network enables cells to migrate. Actin is extremely abundant in most cells, comprising 1–5% of the total protein mass of most cells, and 10% of muscle cells. The actin protein is found in both the cytoplasm and the cell nucleus. Its location is regulated by cell membrane signal transduction pathways that integrate the stimuli that a cell receives stimulating the restructuring of the actin networks in response. The role of actin as a regulator of chemical processes in the cell cytoplasm was proposed. The cytoplasm is viscous, crowded, and heterogeneous, a dynamic complex, a gel-like substance that restricts free diffusion but is capable of managing a myriad of reactions at any moment. The high capacity of the cytoplasm to perform complex chemical reactions can be explained by a two-phase system of organization, in which catalytic complexes are immobilized in the elastic solid phase (cytomatrix), thereby overcoming spatial hindrances and crowding. Nutrients and substrates can be delivered by liquid-phase (cytosol) flux, and the motor protein actin provides the driving force for cytomatrix mechanics. Approximately 150 actin-binding and regulatory proteins fine-tune metabolic processes in the cytoplasm, thereby overcoming cytoplasmic viscosity. The energy source for actin dynamics in normal physiological conditions is mitochondria.
=== Parallel thermal shift assays === Recent developments have extended thermal shift approaches to the analysis of ligand interactions in complex mixtures, including intact cells. Initial observations of individual proteins using fast parallel proteolysis (FastPP) showed that stabilization by ligand binding could impart resistance to proteolytic digestion with thermolysin. Protection relative to reference was quantified through either protein staining on gels or western blotting with a labeling antibody directed to a tag fused to the target protein. CETSA, for cellular thermal shift assay, is a method that monitors the stabilization effect of drug binding through the prevention of irreversible protein precipitation, which is usually initiated when a protein becomes thermally denatured. In CETSA, aliquots of cell lysate are transiently heated to different temperatures, following which samples are centrifuged to separate soluble fractions from precipitated proteins. The presence of the target protein in each soluble fraction is determined by western blotting and used to construct a CETSA melting curve that can inform regarding in vivo targeting, drug distribution, and bioavailability. Both FastPP and CETSA generally require antibodies to facilitate target detection, and consequently are generally used in contexts where the target identity is known a priori.
==== Effectors ==== Pseudomonas syringae isolates carry a range of virulence factors called type III secretion system (T3SS) effector proteins. These proteins primarily function to cause disease symptoms and manipulate the host's immune response to facilitate infection. The major family of T3SS effectors in P. syringae is the hrp gene cluster, coding for the Hrp secretion apparatus.
Sources: en.wikipedia.org
==== Moving ==== Employer-paid moving expense benefits were temporarily considered taxable income to the employee, but they are now permanently taxable income. Moving expense benefits for employees who are active-duty members of the U.S. Armed Forces or members of the U.S. Intelligence Community continue to be tax-free to the employee.
His observations culminated in the Political Essay on the Island of Cuba, a comprehensive geographic study examining the island’s physical and economic conditions, as well as the social realities of slavery. Published in 1828, the work was notable for its data and its condemnation of slavery, resonating during the Latin American independence movements. If the legislation of the Antilles and the condition of the colored population does not experience some salutary change, and if discussion without action is continued, the political power may well pass into the hands of that class which holds the might of labor, the will to throw off the yoke Humboldt also analyzed demographic data. In Cumana, he had recorded 6,000 people of color among 110,000 white and Creole residents. In Havana, government archives revealed that more than 2,130,000 Africans had been forcibly transported to British Caribbean territories over the previous century. In 1806, the slave trade involved 53,000 sales in British dominions and 15,000 in the United States. Humboldt estimated that from 1670 to 1825, nearly five million Africans were brought to the West Indies, not counting deaths during the Middle Passage. He was deeply affected by the realities of slavery, expressing indignation and advocating for strict enforcement of anti-slavery laws. He hoped that anti-slavery principles would spread southward in the Americas. The journey through Cuba was shortened when Humboldt received news of Captain Baudin’s French scientific expedition, expected on the Peruvian coast within a year.
Abdel Fattah al-Burhan Abdelrahman al-Burhan (born 11 July 1960) is a Sudanese military officer who has been the leader of Sudan since 2019. Following the Sudanese Revolution in April 2019, he was handed control of the military junta, the Transitional Military Council, a day after it was formed, due to protesters' dissatisfaction with the establishment ties of initial leader Ahmed Awad Ibn Auf. He served as chairman of the TMC until a draft constitutional declaration signed with civilians went into effect on 17 August and a collective head of state Transitional Sovereignty Council was formed on 21 August, also to be initially headed by al-Burhan. The 2020 Juba Agreement allowed al-Burhan to continue to lead the Sovereignty Council for another 20 months, rather than stepping down as planned in February 2021. Al-Burhan seized power in a coup d'état in October 2021, dissolved the Sovereignty Council, and reconstituted it the following month with new membership, keeping himself as chairman. He was formerly the General Inspector of the Sudanese Armed Forces (SAF). He is leading the SAF against the Rapid Support Forces (RSF) in the ongoing Sudanese civil war. Al-Burhan survived an assassination attempt in July 2024.
The deal was to constitute a reverse merger, whereby Allergan acquired Pfizer, with the new company then changing its name to "Pfizer, plc". On April 6, 2016, Pfizer and Allergan terminated the merger agreement after the Obama administration and the United States Department of the Treasury introduced new laws intended to limit corporate inversions (the extent to which companies could move their headquarters overseas in order to reduce the amount of taxes they pay). In June 2016, the company acquired Anacor Pharmaceuticals for $5.2 billion, expanding its portfolio in both inflammation and immunology drugs areas. In August 2016, the company made a $40 million bid for the assets of BIND Therapeutics, which was in bankruptcy. The same month, the company acquired Bamboo Therapeutics for $645 million, expanding its gene therapy offerings. In September 2016, the company acquired cancer drug-maker Medivation for $14 billion. In October 2016, the company licensed the anti-CTLA4 monoclonal antibody, ONC-392, from OncoImmune. In November 2016, Pfizer funded a $3,435,600 study with the CDC Foundation to research "screen-and-treat" strategies for cryptococcal disease in Botswana. In December 2016, Pfizer acquired AstraZeneca's small-molecule antibiotics business for $1.575 billion. In January 2018, Pfizer announced that it would end its work on research into treatments for Alzheimer's disease and Parkinsonism (a symptom of Parkinson's disease and other conditions). The company said about 300 researchers would lose their jobs.
Sources: en.wikipedia.org
The principal difference is a chemical cap on the N-terminal tyrosine that prevents rapid enzymatic cleavage. Native GHRH is degraded within minutes in plasma, whereas the modified peptide persists considerably longer. The amino acid backbone otherwise mirrors the natural hormone.
No. It is a receptor agonist that stimulates the pituitary to release endogenous growth hormone. It does not contain or deliver growth hormone. Its downstream effects therefore depend on a functioning pituitary and an intact signaling pathway.
Pituitary responsiveness, receptor availability, and the natural pulsatility of the growth hormone axis all contribute. Because the compound amplifies an existing release pattern rather than overriding it, timing and physiological state matter. Individual variability in response is well documented but not fully explained.
It is a laboratory-made peptide that mimics growth hormone-releasing hormone. It prompts the pituitary gland to release growth hormone and has been studied mainly in adults with HIV-associated lipodystrophy.